Health Care & Life Sciences » Biotechnology | Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
7,956.00
5,734.00
3,061.00
2,536.00
669.00
237
SG&A Expense
39,709.00
50,748.00
42,336.00
38,985.00
35,079.00
25,938
EBIT
31,773.00
45,043.00
39,302.00
36,460.00
34,419.00
25,710
Unusual Expense
96.00
3,892.00
3,543.00
-
-
-
Non Operating Income/Expense
4.00
132.00
22.00
158.00
357.00
249
Interest Expense
2,917.00
1,719.00
939.00
1,721.00
1,396.00
1,154
Pretax Income
34,598.00
43,002.00
36,676.00
38,023.00
35,458.00
26,615
Consolidated Net Income
34,598.00
43,002.00
36,676.00
38,023.00
35,458.00
26,615
Net Income
34,598.00
43,002.00
36,676.00
38,023.00
35,458.00
26,615
Net Income After Extraordinaries
34,598.00
43,002.00
36,676.00
38,023.00
35,458.00
26,615
Net Income Available to Common
34,598.00
43,002.00
36,676.00
38,023.00
35,458.00
26,615
EPS (Basic)
3.97
4.56
3.00
2.42
1.45
0.75
Basic Shares Outstanding
8,708.20
10,009.50
12,155.50
15,688.00
24,516.00
35,582
EPS (Diluted)
3.97
4.57
3.02
2.42
1.45
0.75
Diluted Shares Outstanding
8,708.20
10,251.70
12,155.50
15,688.00
24,516.00
35,582
EBITDA
31,753.00
45,014.00
39,275.00
36,449.00
34,410.00
25,701

About Sunesis Pharmaceuticals

View Profile
Address
395 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.sunesis.com
Updated 07/08/2019
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.